Merck launches multiple sclerosis therapy Mavenclad in UK

Merck has announced that its new multiple sclerosis therapy Mavenclad has been made available in the UK and Ireland.

The oral tablet-based therapy is approved for the treatment of adult patients with highly active relapsing multiple sclerosis, and represents the first oral short-course treatment to provide efficacy across key measures of disease activity in this patient group.

An extensive 12-year clinical trial programme that included three phase III trials showed that Mavenclad delivered improvements in disability progression, annualised relapse rates and magnetic resonance imaging activity, as well as a well-characterised safety profile.

It can sustain disease control for up to four years with a maximum of 20 days of tablets in the first two years, as well as offering the lowest treatment and monitoring burden of all available disease-modifying treatments for highly active relapsing multiple sclerosis.

Marco Lyons, head of medical neurology and immunology at Merck, said: "Merck is invested in improving the care of patients with multiple sclerosis and alongside our new patient support programme Adveva, this is an important milestone that demonstrates our commitment."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.